

REMARKS

Claims 13-25 are now pending, with claim 13 being the sole independent claim.

Claims 1-12 have been canceled without prejudice to or disclaimer of the subject matter recited therein.

Claims 13-25 have been added. Support for the sequence identities recited in claims 13-25 is found at least in the paragraph at page 6, lines 13-27, of the specification. Support for the use of the term "recombinant" in claims 19, 21, 23 and 24 is found at least in the paragraph at page 10, lines 26-29, of the specification. Support for claims 22-24 are found at least in Examples 4-5, pages 18-22 of the specification. No new matter has been added.


RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement in the Office Action mailed July 26, 2002, Applicants hereby elect, without traverse, Group III, claims 1-5, and 7, drawn to the nucleic acid of SEQ ID NO:5, a chimeric gene comprising the nucleic acid, a host cell comprising the chimeric gene, and a method of use of the chimeric gene, classified in class 536, subclass 23.2. Applicants submit that now pending Claims 13-25 are directed to Group III, concerning SEQ ID NO:5 or a nucleic acid sequence encoding SEQ ID NO:6.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,



J. KENNETH JOUNG
Attorney For Applicants
Registration No. 41,881
Telephone: 302-992-4929
Facsimile: 302-892-1026

Dated: 30 December 2002